Table 3.
Survival to discharge home, treatments and morbidities of those receiving intensive care
| 1991–1992 | 1997 | 2005 | 2016–2017* | ||||
| n=332 | n=190 | n=229 | n=250 | ||||
| N (%) | Adj OR (95% CI), p value† | N (%) | Adj OR (95% CI), p value† |
N (%) | Adj OR (95% CI), p value† |
N (%) | |
| Survival to discharge home | 227 (68.4) | 0.24 (0.15 to 0.38), p<0.001 | 152 (80.0) | 0.61 (0.35 to 1.06), p=0.08 | 170 (74.2) | 0.41 (0.25 to 0.68), p=0.001 | 217 (86.8) |
| Surfactant | 151 (45.5) | 0.19 (0.12 to 0.28), p<0.001 | 162 (85.3) | 1.21 (0.72 to 2.03), p=0.47 | 205 (89.5) | 1.94 (1.13 to 3.34), p=0.02 | 202/247 (81.8) |
| IVH 3 or 4 | 46 (13.9) | 1.53 (0.89 to 2.62), p=0.12 | 19 (10.0) | 0.97 (0.51 to1.87), p=0.94 | 35 (15.3) | 1.59 (0.89 to 2.83), p=0.11 | 27/249 (10.8) |
| cPVL | 21 (6.3) | 5.47 (1.62 to 18.5), p=0.01 | 11 (5.8) | 5.09 (1.35 to 19.1), p=0.02 | 6 (2.6) | 2.22 (0.54 to 9.15), p=0.27 | 3 (1.2) |
| NEC | 30/331 (9.1) | 0.56 (0.33 to 0.95), p=0.03 | 12 (6.3) | 0.35 (0.17 to 0.71), p=0.003 | 32 (14.0) | 0.91 (0.54 to 1.53), p=0.71 | 37 (14.8) |
| ROP received treatment‡ | 13/331 (3.9) | 0.45 (0.21 to 0.97), p=0.04 | 11/187 (5.9) | 0.49 (0.21 to 1.11), p=0.09 | 10/219 (4.6) | 0.38 (0.16 to 0.89), p=0.03 | 25/249 (10.0) |
| BPD (Oxygen at 36 weeks)§ | 116/237 (48.9) | 1.21 (0.80 to 1.81), p=0.37 | 68/153 (44.4) | 0.76 (0.47 to 1.23), p=0.26 | 106/182 (58.2) | 1.65 (1.07 to 2.52), p=0.02 | 108/220 (49.1) |
| Survival to discharge home free of major morbidities¶ | 99 (29.8) | 0.58 (0.39 to 0.86), p=0.01 | 73 (38.4) | 1.11 (0.71 to 1.76), p=0.64 | 62 (27.1) | 0.58 (0.38 to 0.89), p=0.01 | 94 (37.6) |
| Postnatal corticosteroids | 108 (32.5) | 1.17 (0.81 to 1.71), p=0.40 | 81 (42.6) | 1.48 (0.96 to 2.28), p=0.08 | 55 (24.0) | 0.63 (0.41 to 0.98), p=0.04 | 77 (30.8) |
| Surgery | 77 (23.2) | 0.94 (0.63 to 1.39), p=0.74 | 53 (27.9) | 1.06 (0.68 to 1.67), p=0.79 | 70 (30.6) | 1.32 (0.86 to 2.01), p=0.20 | 62 (24.8) |
*2016–2017 cohort as a reference for all comparisons.
†Adjusted for inborn status (ie, birth in a tertiary perinatal centre), gestation at birth, sex, birth weight z-score.
‡Laser or cryotherapy (1991–1992, 1997 and 2005); Bevacizumab injections and/or laser therapy (2016–2017).
§Denominator—alive at 36 weeks postmenstrual age.
¶Major morbidities include IVH 3 or 4, cPVL, NEC, ROP received treatment and/or bronchopulmonary dysplasia.
BPD, bronchopulmonary dysplasia; cPVL, cystic periventricular leukomalacia; IVH 3 or 4, intraventricular haemorrhage grade 3 or 4; NEC, necrotising enterocolitis Bell stage 2 or worse; ROP, retinopathy of prematurity.